INCY
Incyte develops small molecule drugs and targeted therapies for oncology, hematology, and inflammatory diseases. The company has multiple FDA-approved products on the market, including JAKAFI (ruxolitinib) for blood disorders, PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib) for certain cancers, and MONJUVI (tafasitamab) for lymphoma, alongside several earlier-stage drug candidates in clinical development. Incyte operates across discovery, clinical development, and commercialization stages, with an established commercial infrastructure to market approved drugs.
Pipeline
Anti-VEGF-A monoclonal antibody (Avastin) that inhibits tumor angiogenesis. Approved for colorectal, ovarian, breast, glioblastoma, and other solid tumors.
Platinum-based chemotherapy that forms DNA crosslinks, inducing apoptosis in cancer cells. Standard of care across many solid tumors including NSCLC, ovarian, breast, bladder, and biliary cancers.
Platinum-based chemotherapy that forms DNA crosslinks. Foundational cytotoxic agent used across testicular, bladder, ovarian, head and neck, and lung cancers.
Alkylating chemotherapy that forms DNA crosslinks. Backbone in lymphoma (R-CHOP), breast cancer, and as conditioning regimen for stem cell transplant.
Anthracycline chemotherapy that intercalates DNA and inhibits topoisomerase II. Backbone agent in breast cancer, lymphoma, leukemia, and sarcoma regimens.
Oral immunomodulatory drug (Revlimid) that recruits IKZF1/IKZF3 to cereblon for degradation. Standard in multiple myeloma, MDS, and follicular lymphoma.
Albumin-bound paclitaxel (Abraxane) with improved delivery and reduced solvent toxicity. Used in metastatic breast cancer, NSCLC, and pancreatic adenocarcinoma.
Taxane chemotherapy that binds β-tubulin and prevents microtubule depolymerization, causing mitotic arrest. Used in breast, ovarian, lung, and other cancers.
Multi-targeted antifolate chemotherapy used in non-squamous NSCLC and mesothelioma, typically combined with platinum agents.
Oral synthetic corticosteroid used as anti-inflammatory and immunosuppressant. Backbone in lymphoma regimens (R-CHOP, BEACOPP) and supportive care.
Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production.
Chimeric anti-CD20 monoclonal antibody (Rituxan) that depletes B cells via ADCC, CDC, and apoptosis. Foundational in B-cell lymphomas, CLL, rheumatoid arthritis, and ANCA vasculitis.
Oral selective JAK1/JAK2 inhibitor (Jakafi) that blocks JAK-STAT signaling. Approved in myelofibrosis, polycythemia vera, GVHD, and topically in atopic dermatitis.
Tafasitamab-cxix is an Fc-modified monoclonal antibody that binds to CD19 antigen expressed on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
Vinca alkaloid chemotherapy that inhibits microtubule polymerization, arresting mitosis. Used in lymphomas (R-CHOP), leukemias, and pediatric cancers.
Axatilimab-csfr is a monoclonal antibody that binds to colony stimulating factor-1 receptors (CSF-1R) expressed on monocytes and macrophages.
Oral 5-fluorouracil prodrug activated to 5-FU in tumor tissue. Used in colorectal, breast, and gastric cancers, often combined with oxaliplatin or platinum.
Pemigatinib is a small molecule kinase inhibitor that targets FGFR1, 2 and 3 with IC 50 values of less than 2 nM. Pemigatinib also inhibited FGFR4 in vitro at a concentration approximately 100 times higher than those that inhibit FGFR1, 2, and 3.
Oral pan-BCR-ABL tyrosine kinase inhibitor (Iclusig) active against the T315I mutation. Approved in resistant/intolerant chronic myeloid leukemia and Ph+ ALL.
Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, metastasis and tumor immunity.